Table 2.
Observed SF-36 PCS and MCS scores by visit in the SELECT-NEXT and SELECT-MONOTHERAPY clinical trials
| SELECT-NEXT | SELECT-MONOTHERAPY | |||||||
|---|---|---|---|---|---|---|---|---|
| Upadacitinib 15 mg QDa | Placebob | Upadacitinib 15 mg QD | Methotrexatec | |||||
| n | Visit mean | n | Visit mean | n | Visit mean | n | Visit mean | |
| SF-36 PCS | ||||||||
| Week 0 | 219 | 33.4 | 221 | 33.1 | 217 | 33.3 | 216 | 33.3 |
| Week 4 | 217 | 39.0 | 219 | 36.2 | 212 | 39.1 | 213 | 35.6 |
| Week 12 | 213 | 41.4 | 213 | 36.9 | – | – | – | – |
| Week 14 | – | – | – | – | 203 | 41.2 | 202 | 37.0 |
| Week 24 | 200 | 42.8 | 196 | 42.5 | – | – | – | – |
| Week 48 | 179 | 44.1 | 186 | 44.1 | 168 | 44.1 | 184 | 43.6 |
| SF-36 MCS | ||||||||
| Week 0 | 219 | 45.9 | 221 | 46.5 | 217 | 44.1 | 216 | 45.1 |
| Week 4 | 217 | 49.0 | 219 | 48.2 | 212 | 48.1 | 213 | 46.8 |
| Week 12 | 213 | 50.3 | 213 | 48.7 | – | – | – | – |
| Week 14 | – | – | – | – | 203 | 49.2 | 202 | 47.2 |
| Week 24 | 200 | 51.8 | 196 | 51.1 | – | – | – | – |
| Week 48 | 179 | 51.4 | 186 | 51.8 | 168 | 50.2 | 184 | 49.7 |
MCS Mental Component Summary, PCS Physical Component Summary, QD once daily, SF-36 36-Item Short-Form Health Survey
aIn SELECT-NEXT, patients were on stable background csDMARD therapy
bIn SELECT-NEXT, patients in the placebo group received upadacitinib after week 12; therefore, the medical cost estimation used SF-36 outcomes carried forward from week 12 in the placebo group
cIn SELECT-MONOTHERAPY, patients in the methotrexate group received upadacitinib after week 14; therefore, the medical cost estimation used SF-36 outcomes carried forward from week 14 in the methotrexate group